Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell Lymphoma

Talal Hilal, MB, BCh
Published: Friday, Jun 08, 2018



Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab (Rituxan) maintenance for patients with mantle cell lymphoma.

In the overall population, there was a benefit in terms of progression-free survival (PFS) and overall survival (OS) in all of the studies. In the prospective studies, the benefit was mainly PFS—there was no OS benefit. Only 3 prospective trials were included in the analysis, and only 1 used transplant. That, says Hilal, is the main driver of OS benefit in these studies.

The retrospective studies have their own limitations, states Hilal. There was a lot of heterogeneity and differences in how patients were treated. In the transplant only group, there were a couple patients who were excluded because they did not undergo transplant. In those studies, there was a PFS benefit as well, but no OS benefit.

Therefore, patients who are young, fit, and eligible for transplant should be started with an induction chemoimmunotherapy that includes cytarabine-based regimens and rituximab maintenance. It is still a question as to whether this regimen is appropriate for older patients and patients who are not eligible for transplant, says Hilal.


Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab (Rituxan) maintenance for patients with mantle cell lymphoma.

In the overall population, there was a benefit in terms of progression-free survival (PFS) and overall survival (OS) in all of the studies. In the prospective studies, the benefit was mainly PFS—there was no OS benefit. Only 3 prospective trials were included in the analysis, and only 1 used transplant. That, says Hilal, is the main driver of OS benefit in these studies.

The retrospective studies have their own limitations, states Hilal. There was a lot of heterogeneity and differences in how patients were treated. In the transplant only group, there were a couple patients who were excluded because they did not undergo transplant. In those studies, there was a PFS benefit as well, but no OS benefit.

Therefore, patients who are young, fit, and eligible for transplant should be started with an induction chemoimmunotherapy that includes cytarabine-based regimens and rituximab maintenance. It is still a question as to whether this regimen is appropriate for older patients and patients who are not eligible for transplant, says Hilal.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x